10x Genomics (TXG) Current Leases (2020 - 2026)

10x Genomics (TXG) has 7 years of Current Leases data on file, last reported at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 19.98% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (up 19.98% YoY), and the FY2025 full-year result was $11.0 million, up 18.3% from the prior year.
• Current Leases improved to $11.3 million in Q1 2026, from $11.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $11.5 million in Q4 2023 to a low of $7.6 million in Q1 2022.
• A 5-year average of $9.7 million and a median of $9.4 million in 2025 frame the typical range for Current Leases.
• Across the five-year window, Current Leases surged 88.02% in 2022 and dropped 19.4% in 2024, its largest moves.
• Tracing TXG's Current Leases over 5 years: stood at $9.0 million in 2022, then rose by 27.49% to $11.5 million in 2023, then declined by 19.4% to $9.3 million in 2024, then rose by 18.3% to $11.0 million in 2025, then advanced by 3.14% to $11.3 million in 2026.
• Business Quant data shows TXG's Current Leases at $11.3 million in Q1 2026, $11.0 million in Q4 2025, and $10.5 million in Q3 2025.